This study is looking at how a drug called Dalcetrapib affects heart health in people who have a specific genetic type and have recently had a heart problem called an Acute Coronary Syndrome (ACS), like a heart attack. In this study, some people will get Dalcetrapib and others will get a placebo, which is a pill with no active drug. It's a double-blind study, meaning neither the participants nor the researchers know who is getting the real drug.

Participants need to be over 45 years old and have a specific genetic marker called the AA genotype. The study lasts until about 200 people experience certain heart-related events. Visits can be virtual every 3 months or in the clinic.

• The study lasts until around 200 heart-related events occur.
• Participants need to be over 45 and have the AA genotype.
• Visits might be virtual every 3 months, depending on circumstances.